COST/UTILITY ANALYSIS (CUA) OF VALSARTAN FOR THE TREATMENT OF CONGESTIVE HEART FAILURE (CHF) IN ITALY BASED ON THE VAL-HEFT TRIAL

被引：0
|
作者：
Pradelli, L. [1 ]
Iannazzo, S. [1 ]
Zaniolo, O. [1 ]
机构：
[1] AdRes Srl, Turin, Italy
来源：
VALUE IN HEALTH | 2008年 / 11卷 / 06期
关键词：
D O I：
10.1016/S1098-3015(10)66370-X
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A403 / A404
页数：2
相关论文
共 50 条
  • [21] Baseline predictors of adverse events with chronic valsartan therapy in symptomatic heart failure. Results from Val-HeFT trial
    Tognoni, G
    Latini, R
    Maggioni, AP
    Barlera, S
    Masson, S
    Anand, IS
    Cohn, JN
    EUROPEAN HEART JOURNAL, 2003, 24 : 176 - 176
  • [22] Valsartan shows consistent efficacy across heart failure patient subgroups: results from Val-HeFT
    Maggioni, A
    Carson, P
    Soler, J
    Chiang, YT
    Aknay, N
    Cohn, JN
    EUROPEAN HEART JOURNAL, 2002, 23 : 327 - 327
  • [23] Baseline and serial measurements of galectin-3 in patients with heart failure: relationship to prognosis and effect of treatment with valsartan in the Val-HeFT
    Anand, Inder S.
    Rector, Thomas S.
    Kuskowski, Michael
    Adourian, Aram
    Muntendam, Pieter
    Cohn, Jay N.
    EUROPEAN JOURNAL OF HEART FAILURE, 2013, 15 (05) : 511 - 518
  • [24] Heart rate variability in the LF band is closely related to BNP levels in heart failure. Data from the multicenter Valsartan Heart Failure Trial (Val-HeFT)
    Mortara, A.
    Krum, H.
    Sondermejer, H.
    Barlera, S.
    Maestri, R.
    Masson, S.
    Latini, R.
    Tavazzi, L.
    EUROPEAN HEART JOURNAL, 2006, 27 : 15 - 15
  • [25] Pharmacoeconomic analysis of valsartan for the treatment of chronic congestive heart failure in Italy
    Zaniolo, Orietta Y.
    Sacchi, Viola
    Pradelli, Lorenzo
    FARMECONOMIA-HEALTH ECONOMICS AND THERAPEUTIC PATHWAYS, 2008, 9 (03) : 137 - 146
  • [26] Prognostic value of changes in N-terminal pro-brain natriuretic peptide in Val-HeFT (Valsartan Heart Failure Trial)
    Masson, Serge
    Latini, Roberto
    Anand, Inder S.
    Barlera, Simona
    Angelici, Laura
    Vago, Tarcisio
    Tognoni, Gianni
    Cohn, Jay N.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2008, 52 (12) : 997 - 1003
  • [27] Effect of valsartan added to background ACE inhibitor therapy in patients with heart failure: results from Val-HeFT
    Krum, H
    Carson, P
    Farsang, C
    Maggioni, AP
    Glazer, RD
    Aknay, N
    Chiang, YT
    Cohn, JN
    EUROPEAN JOURNAL OF HEART FAILURE, 2004, 6 (07) : 937 - 945
  • [28] The prognostic value of big endothelin-1 in more than 2,300 patients with heart failure enrolled in the Valsartan Heart Failure Trial (Val-HeFT)
    Masson, Serge
    Latini, Roberto
    Anand, Inder S.
    Barlera, Simona
    Judd, Dianne
    Salio, Monica
    Perticone, Francesco
    Perini, Giampaolo
    Tognoni, Gianni
    Cohn, Jay N.
    JOURNAL OF CARDIAC FAILURE, 2006, 12 (05) : 375 - 380
  • [29] Elevated Plasma Renin Activity Predicts Adverse Outcome in Chronic Heart Failure, Independently of Pharmacologic Therapy: Data From the Valsartan Heart Failure Trial (Val-HeFT)
    Masson, Serge
    Solomon, Scott
    Angelici, Laura
    Latini, Roberto
    Anand, Inder S.
    Prescott, Margaret
    Maggioni, Aldo P.
    Tognoni, Gianni
    Cohn, Jay N.
    JOURNAL OF CARDIAC FAILURE, 2010, 16 (12) : 964 - 970
  • [30] The prognostic value of body mass index in patients with heart failure: data from the Val-HeFT trial
    Maggioni, AP
    Latini, R
    Anand, I
    Cardano, P
    Wong, M
    Cohn, J
    EUROPEAN HEART JOURNAL, 2003, 24 : 361 - 361
12345